ABSI Stock Price, Absci Corporation Quote, Chart

Market Summary

USD5.09+0.11

Market Closed

2.21%

ABSI Stock Price

View Fullscreen

ABSI RSI Chart

ABSI Valuation

Market Cap

574.1M

Price/Earnings (Trailing)

-5.19

Price/Sales (Trailing)

100.4

EV/EBITDA

-5.26

Price/Free Cashflow

-8.77

ABSI Price/Sales (Trailing)

ABSI Profitability

EBT Margin

-1931.90%

Return on Equity

-62.76%

Return on Assets

-50.88%

Free Cashflow Yield

-11.41%

ABSI Fundamentals

ABSI Revenue

Revenue (TTM)

5.7M

Rev. Growth (Yr)

-78.29%

Rev. Growth (Qtr)

-54.57%

ABSI Earnings

Earnings (TTM)

-110.6M

Earnings Growth (Yr)

-20.92%

Earnings Growth (Qtr)

-7.05%

Breaking Down ABSI Revenue

Last 7 days

11.1%

Last 30 days

-4.1%

Last 90 days

14.9%

Trailing 12 Months

288.6%

How does ABSI drawdown profile look like?

ABSI Financial Health

Current Ratio

4.08

ABSI Investor Care

Shares Dilution (1Y)

0.59%

Diluted EPS (TTM)

-1.2

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	6.2M	8.6M	6.9M	5.7M
2022	4.7M	4.7M	5.5M	5.7M
2021	4.8M	4.9M	4.9M	4.9M
2020	0	0	0	4.8M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Absci Corporation

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 19, 2024	mcclain sean	acquired	-	-	1,500,000	chief executive officer
Mar 01, 2024	redmile group, llc	bought	999,999	4.5	222,222	-
Feb 01, 2024	busch andreas	acquired	-	-	83,125	chief innovation officer
Feb 01, 2024	mcclain sean	acquired	-	-	182,000	chief executive officer
Feb 01, 2024	jonasson zachariah	acquired	-	-	114,010	cfo / cbo
Feb 01, 2024	bedrick todd	acquired	-	-	20,570	svp, cao
Nov 28, 2023	phoenix venture partners ii lp	sold	-58,248	1.4404	-40,439	-
Nov 27, 2023	phoenix venture partners ii lp	sold	-18,165	1.4018	-12,959	-
Nov 24, 2023	phoenix venture partners ii lp	sold	-15,326	1.4219	-10,779	-
Nov 22, 2023	phoenix venture partners ii lp	sold	-4,927	1.4047	-3,508	-

Which funds bought or sold ABSI recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 02, 2024	ARS Investment Partners, LLC	new	-	113,600	113,600	0.01%
May 02, 2024	Nikko Asset Management Americas, Inc.	new	-	2,386,000	2,386,000	0.02%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
May 01, 2024	CAPSTONE INVESTMENT ADVISORS, LLC	new	-	1,476,810	1,476,810	-%
Apr 30, 2024	Institute for Wealth Management, LLC.	unchanged	-	359,467	1,379,580	0.18%
Apr 25, 2024	Mendota Financial Group, LLC	unchanged	-	148	568	-%
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-37.2	-46,393	261,378	-%
Apr 24, 2024	CENTRAL TRUST Co	unchanged	-	1,184	4,544	-%
Apr 23, 2024	Alpha Cubed Investments, LLC	new	-	85,194	85,194	-%
Apr 23, 2024	Global Retirement Partners, LLC	unchanged	-	3,300	11,360	-%

Are Funds Buying or Selling ABSI?

Are funds buying ABSI calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ABSI

No. of Funds

Unveiling Absci Corporation's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 05, 2024	redmile group, llc	4%	8,282,016	SC 13D/A
Feb 14, 2024	phoenix venture partners ii lp	15.5%	14,379,522	SC 13G/A
Feb 13, 2024	mcclain sean	10.0%	9,373,113	SC 13G
Feb 09, 2024	fmr llc	-	0	SC 13G/A
May 08, 2023	casdin capital, llc	4.8%	4,448,260	SC 13D/A
Mar 20, 2023	casdin capital, llc	6.%	5,533,260	SC 13D/A
Feb 14, 2023	phoenix venture partners ii lp	15.7%	14,492,813	SC 13G/A
Feb 14, 2023	mcclain sean	9.8%	9,083,128	SC 13G/A
Feb 13, 2023	casdin capital, llc	7.0%	6,473,260	SC 13D/A
Feb 13, 2023	absci corp	9.8%	9,083,128	SC 13G

Recent SEC filings of Absci Corporation

View All Filings

Date Filed	Form Type	Document
Apr 23, 2024	ARS	ARS
Apr 23, 2024	DEF 14A	DEF 14A
Apr 23, 2024	DEFA14A	DEFA14A
Mar 21, 2024	10-K	Annual Report
Mar 21, 2024	4	Insider Trading
Mar 21, 2024	8-K	Current Report
Mar 21, 2024	S-8	Employee Benefits Plan
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	SC 13D/A	13D - Major Acquisition
Feb 28, 2024	8-K	Current Report

Peers (Alternatives to Absci Corporation)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	47.9B	6.8B	23.52%	-6.94%	-8.03	7	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.3B	2.0B	0.99%	-25.83%	-58.02	9.62	75.20%	68.82%
BMRN	15.7B	2.5B	-4.94%	-13.58%	76.24	6.34	13.74%	186.89%
INCY	12.1B	3.8B	-2.80%	-18.78%	16.19	3.2	8.58%	129.81%
MID-CAP
APLS	5.7B	396.6M	-16.72%	-43.78%	-10.82	14.42	425.83%	18.94%
BBIO	5.2B	107.9M	-4.79%	106.15%	-9.53	48.09	54.84%	-28.31%
AXSM	3.5B	270.6M	1.74%	5.10%	-14.81	13.09	440.80%	-27.84%
ARWR	3.0B	240.7M	-7.74%	-39.00%	-10.2	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-7.55%	-20.97%	-45.79	3.86	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-4.91%	-11.58%	24.31	4.36	85.90%	-14.05%
NVAX	687.2M	983.7M	8.15%	-35.14%	-1.26	0.7	-50.36%	17.16%
CRBP	408.0M	881.7K	0.99%	345.87%	-9.15	466.16	-77.61%	-5.33%
INO	282.8M	4.9M	-1.94%	21.49%	-2.09	58.11	-54.97%	51.71%
IBIO	6.9M	2.1M	-32.65%	86.79%	-0.25	2.14	-13.45%	66.37%

Absci Corporation News

Latest updates

Absci Corporation Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3
Revenue	-54.6%	338,000	744,000	3,367,000	1,269,000	1,557,000	2,369,000	1,002,000	819,000	1,292,500	1,539,000	1,047,000	1,063,000	989,500	916,000
Operating Expenses	4.3%	25,077,000	24,047,000	46,355,000	25,754,000	22,650,000	30,336,000	29,889,000	29,622,000	27,708,000	22,681,000	17,420,000	12,211,000	-	4,280,000
S&GA Expenses	-1.9%	9,324,000	9,505,000	9,410,000	9,593,000	7,749,000	11,407,000	10,507,000	10,889,000	9,183,000	9,733,000	5,179,000	4,685,000	-	1,257,000
R&D Expenses	11.2%	12,269,000	11,029,000	12,112,000	12,657,000	11,315,000	15,525,000	16,241,000	15,827,000	15,766,000	10,730,000	11,040,000	7,050,000	-	2,692,000
EBITDA Margin	-26.2%	-16.69	-13.23	-11.38	-13.73	-15.90	-17.98	-20.86	-24.49	-20.19	-2.57	-2.59	-2.61	-2.63	-
Interest Expenses	-10.9%	204,000	229,000	256,000	321,000	287,000	279,000	211,000	195,000	200,000	768,000	2,009,000	455,000	-	172,000
Income Taxes	41.2%	48,000	34,000	11,000	7,000	-500,000	-312,000	-270,000	621,000	-1,099,000	-1,703,000	-5,600,000	-500,000	-	-
Earnings Before Taxes	-7.0%	-23,497,000	-21,960,000	-41,661,000	-23,348,000	-19,971,000	-27,571,000	-28,950,000	-28,873,000	-26,268,000	-25,337,000	-46,815,000	-11,439,000	-	-3,748,000
EBT Margin	-25.3%	-19.32	-15.42	-13.15	-16.11	-18.33	-20.37	-23.52	-27.10	-22.23	-2.93	-2.95	-2.98	-3.00	-
Net Income	-7.1%	-23,545,000	-21,994,000	-41,672,000	-23,355,000	-19,471,000	-27,259,000	-28,680,000	-29,494,000	-25,166,000	-23,634,000	-41,198,000	-10,962,000	-4,939,000	-3,748,000
Net Income Margin	-26.0%	-19.34	-15.35	-13.05	-15.94	-18.25	-20.17	-22.99	-25.44	-20.43	-16.47	-12.52	-4.70	-3.00	-
Free Cashflow	-40.0%	-14,939,000	-10,668,000	-19,490,000	-20,399,000	-19,128,000	-23,913,000	-26,467,000	-28,006,000	-25,395,000	-27,367,000	-32,234,000	-13,649,000	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet												(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	-8.1%	217	236	254	296	321	339	366	395	426	449	257	89.00
Current Assets	-10.5%	121	135	148	165	187	201	228	256	273	301	112	73.00
Cash Equivalents	3.8%	72.00	70.00	61.00	11.00	60.00	124	223	251	280	307	127	72.00
Goodwill	-	-	-	-	21.00	21.00	21.00	21.00	21.00	21.00	23.00	23.00	-
Liabilities	3.0%	41.00	40.00	39.00	42.00	47.00	46.00	50.00	55.00	60.00	61.00	220	22.00
Current Liabilities	5.7%	30.00	28.00	25.00	27.00	30.00	30.00	32.00	42.00	34.00	30.00	30.00	10.00
Shareholder's Equity	-10.3%	176	196	215	254	274	293	316	340	366	388	-	-
Retained Earnings	-6.1%	-406	-382	-360	-319	-295	-276	-249	-220	-191	-165	-142	-90.06
Additional Paid-In Capital	0.6%	583	579	576	573	570	569	565	561	557	554	18.00	1.00
Shares Outstanding	0.2%	93.00	93.00	93.00	92.00	92.00	93.00	91.00	90.00	93.00	73.00	17.00	18.00
Float	-	-	-	92.00	-	-	-	176	-	-	-	1,200	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)															(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Cashflow From Operations	-44.0%	-14,922	-10,361	-19,234	-20,119	-18,568	-19,043	-22,579	-21,149	-17,079	-21,747	-14,487	-7,285	-	-	-
Share Based Compensation	25.0%	3,179	2,544	3,041	2,652	1,024	3,567	4,209	3,740	3,232	3,783	1,441	2,152	-	-	-
Cashflow From Investing	-5.8%	18,958	20,135	70,152	-27,301	-30,179	-78,723	-11,223	-6,857	-8,316	-6,820	-43,365	-8,876	-	-	-
Cashflow From Financing	-33.7%	-1,235	-924	-1,220	-1,104	1,393	-921	5,823	-1,058	-1,296	208,387	-474	129,576	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ABSI Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenues
Technology development revenue	$ 5,718	$ 4,529
Collaboration revenue	0	1,218
Total revenues	5,718	5,747
Operating expenses
Research and development	48,067	58,908
Selling, general and administrative	37,832	40,552
Depreciation and amortization	13,999	13,037
Goodwill impairment	21,335	0
Total operating expenses	121,233	112,497
Operating loss	(115,515)	(106,750)
Other income (expense)
Interest expense	(1,010)	(972)
Other income, net	6,059	2,357
Total other income, net	5,049	1,385
Loss before income taxes	(110,466)	(105,365)
Income tax (expense) benefit	(100)	461
Net loss	$ (110,566)	$ (104,904)
Net loss per share: basic (in usd per share)	$ (1.20)	$ (1.15)
Net loss per share: diluted (in usd per share)	$ (1.20)	$ (1.15)
Weighted-average common shares outstanding: basic (in shares)	92,028,016	90,845,629
Weighted-average common shares outstanding: diluted (in shares)	92,028,016	90,845,629
Comprehensive loss:
Net loss	$ (110,566)	$ (104,904)
Foreign currency translation adjustments	40	(66)
Unrealized gain on investments	43	(41)
Comprehensive loss	$ (110,483)	$ (105,011)
Revenue from Contract with Customer, Product and Service [Extensible Enumeration]	License and Service [Member]

ABSI Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 72,362	$ 59,955
Restricted cash	16,193	15,023
Short-term investments	25,297	104,476
Receivables under development arrangements, net	2,189	1,550
Prepaid expenses and other current assets	4,537	5,859
Total current assets	120,578	186,863
Operating lease right-of-use assets	4,490	5,319
Property and equipment, net	41,328	52,723
Intangibles, net	48,253	51,622
Goodwill	0	21,335
Restricted cash, long-term	1,112	1,864
Other long-term assets	1,537	1,282
TOTAL ASSETS	217,298	321,008
Current liabilities:
Accounts payable	1,503	2,412
Accrued expenses	19,303	20,481
Long-term debt	3,258	2,946
Operating lease obligations	1,679	1,690
Financing lease obligations	641	2,296
Deferred revenue	3,174	445
Total current liabilities	29,558	30,270
Long-term debt, net of current portion	4,660	7,984
Operating lease obligations, net of current portion	5,643	7,317
Finance lease obligations, net of current portion	76	750
Deferred tax liability, net	186	238
Deferred revenue, long-term	966	0
Other long-term liabilities	33	35
TOTAL LIABILITIES	41,122	46,594
Commitments (See Note 9)
STOCKHOLDERS' EQUITY
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding	0	0
Common stock, $0.0001 par value; 500,000,000 shares authorized; 93,087,675 and 92,411,103 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively	9	9
Additional paid-in capital	582,699	570,454
Accumulated deficit	(406,495)	(295,929)
Accumulated other comprehensive loss	(37)	(120)
TOTAL STOCKHOLDERS' EQUITY	176,176	274,414
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 217,298	$ 321,008

About Absci Corporation

Absci Corporation operates as a generative AI drug creation company in the United States. Its integrated drug creation platform identifies novel drug targets and creates biotherapeutic candidates. The company was founded in 2011 and is headquartered in Vancouver, Washington.

CEO	Mr. Sean McClain
WEBSITE	absci.com
INDUSTRY	Biotechnology
EMPLOYEES	193

Absci Corporation Frequently Asked Questions

What is the ticker symbol for Absci Corporation? What does ABSI stand for in stocks?

ABSI is the stock ticker symbol of Absci Corporation. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Absci Corporation (ABSI)?

As of Fri May 03 2024, market cap of Absci Corporation is 574.07 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ABSI stock?

You can check ABSI's fair value in chart for subscribers.

What is the fair value of ABSI stock?

You can check ABSI's fair value in chart for subscribers. The fair value of Absci Corporation is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Absci Corporation is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ABSI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Absci Corporation a good stock to buy?

The fair value guage provides a quick view whether ABSI is over valued or under valued. Whether Absci Corporation is cheap or expensive depends on the assumptions which impact Absci Corporation's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ABSI.

What is Absci Corporation's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 03 2024, ABSI's PE ratio (Price to Earnings) is -5.19 and Price to Sales (PS) ratio is 100.4. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ABSI PE ratio will change depending on the future growth rate expectations of investors.